{"id":938673,"date":"2026-02-20T08:33:45","date_gmt":"2026-02-20T13:33:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference\/"},"modified":"2026-02-20T08:33:45","modified_gmt":"2026-02-20T13:33:45","slug":"calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference\/","title":{"rendered":"Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN DIEGO, Feb.  20, 2026  (GLOBE NEWSWIRE) &#8212; Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (\u201cCalidi\u201d or the \u201cCompany\u201d), a biotechnology company pioneering the development of targeted genetic medicines, today presented data on its novel approach to the use of BiTEs in solid tumors by utilizing its systemically delivered RedTail platform at the AACR Immuno-Oncology (AACR-IO) conference being held in Los Angeles, California. A link to the poster is available <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JFuGdZ33lU65fzR5qZcM7GBpEWzM-MoPAz-gyP9muF7G_HR_4fsaWLN5WNi-5EOPfXVr90U1CmJHiDQCO45ESgNhiHo3_DEn13KQU_JoWt7ZarMVOTfsGK8ZI4mVJHgrlCUmxINU7vHz7bUvo1HJJVqHbIjlZpSXg5VUN3XDXwk=\" rel=\"nofollow\" target=\"_blank\">here<\/a> and on the company\u2019s website.<\/p>\n<p>RedTail is Calidi\u2019s systemically delivered virotherapy platform designed to selectively target tumors, remodel the tumor microenvironment (TME), and enable high-level expression of therapeutic genetic payloads directly within the tumor. CLD-401, the lead candidate derived from the RedTail platform, is engineered to express high levels of IL\u201115 superagonist (IL-15 SA), a known T-cell activator, in the TME.<\/p>\n<p>In data presented at the meeting, Calidi demonstrated RedTail viruses that could express both a functional BiTE, capable of binding targeted solid tumor cells, and IL-15 SA at high concentrations, allowing for simultaneous alteration of the TME and T-cell activation and introduction into the TME of a solid-tumor targeting BiTE. BiTEs have shown exceptional efficacy in hematological malignancies but have failed to show clinical benefit in solid tumors where the TME inhibits T-cell activity. By remodeling the TME and driving T-cell activation while expressing a tumor-localized BiTE, RedTail may overcome the historical limitations of BiTEs in solid tumors.<\/p>\n<p>\u201cThe RedTail platform allows for the systemic and targeted delivery of genetic payloads to distal sites of disease,\u201d said Eric Poma, PhD, Chief Executive Officer of Calidi. \u201cOnce at the target, RedTail can induce high levels of expression of one or more genetic payloads, representing a major advance in the delivery of genetic medicines.\u201d<\/p>\n<p>\u201cThe data presented today highlight the ability of the RedTail platform to functionally overexpress complex biologics likes BiTEs and cytokines directly within the tumor microenvironment,\u201d said Antonio F. Santidrian, PhD, Chief Scientific Officer and Head of Technical Operations at Calidi. \u201cSimultaneous tumor-localized expression of a T-cell activator and BiTE via RedTail can remodel the TME to allow for T-cell engagement precisely where it is needed.\u201d<\/p>\n<p>Calidi is currently conducting IND-enabling studies with CLD-401, the first lead candidate from its RedTail platform. The company anticipates submitting an Investigational New Drug (IND) application for CLD-401 by the end of 2026. The Company continues to expand the functionality of the RedTail platform and is also actively pursuing strategic partnerships to accelerate clinical development and broaden the impact of its RedTail platform.<\/p>\n<p>\n        <strong>About Calidi\u00a0<\/strong>\n      <\/p>\n<p>Calidi Biotherapeutics (NYSE American: CLDI) is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company\u2019s proprietary Redtail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations.<\/p>\n<p>CLD-401, the lead candidate from the Redtail platform, currently in IND-enabling studies, targets non-small cell lung cancer, head and neck cancer, and other tumor types with high unmet medical need. Calidi continues to advance its pipeline utilizing the Redtail platform including its novel approach to incorporate BiTEs in solid tumors.<\/p>\n<p>Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit\u00a0www.calidibio.com\u00a0or view Calidi\u2019s Corporate Presentation\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JFuGdZ33lU65fzR5qZcM7LY7TNCPbijSu_R1qEXezLeAzMuNf5LdowXgqW5ygq51mEoDfkNNd_eZoihfY6cbAriIrPRqbO6Awm2iOfoktRxpHpzKGdqoSEr1u5-3bMj0b7EAEXP903wWawGcuPF5Mg3MPpxJH7fC0wgfRXsZUgc3dKRbV8sn1kbWZpoefNMf\" rel=\"nofollow\" target=\"_blank\">here<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This press release may contain forward-looking statements for purposes of the \u201csafe harbor\u201d provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as \u201canticipates,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredicts,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctowards,\u201d \u201cwould\u201d as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements concerning key milestones, including certain pre-clinical data, planned clinical trials, and statements relating to the safety and efficacy of Calidi\u2019s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi\u2019s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates. Other risks and uncertainties are set forth in the section entitled \u201cRisk Factors\u201d and \u201cCautionary Note Regarding Forward-Looking Statements\u201d in the Company\u2019s annual report filed with the SEC on Form 10-K on March 31, 2025, as may be amended or supplemented by other reports we file with the SEC from time to time. We disclaim any obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.<\/p>\n<p>\n        <strong>For Investors:<\/strong>\n      <\/p>\n<p>Dave Gentry, CEO<br \/>RedChip Companies, Inc.<br \/>1-407-644-4256<br \/>CLDI@redchip.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1ODEyNyM3NDM1Nzg4IzIxOTM4NTQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZTE5MWE3ZTEtOGNlYS00OGU4LWI5OTYtNmM2ZWU3MzhlYTQ1LTEyMDU0MDctMjAyNi0wMi0yMC1lbg==\/tiny\/Calidi-Biotherapeutics-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) &#8212; Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (\u201cCalidi\u201d or the \u201cCompany\u201d), a biotechnology company pioneering the development of targeted genetic medicines, today presented data on its novel approach to the use of BiTEs in solid tumors by utilizing its systemically delivered RedTail platform at the AACR Immuno-Oncology (AACR-IO) conference being held in Los Angeles, California. A link to the poster is available here and on the company\u2019s website. RedTail is Calidi\u2019s systemically delivered virotherapy platform designed to selectively target tumors, remodel the tumor microenvironment (TME), and enable high-level expression of therapeutic genetic payloads directly within the tumor. CLD-401, the lead candidate derived from the RedTail platform, is engineered to express high levels of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-938673","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) &#8212; Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (\u201cCalidi\u201d or the \u201cCompany\u201d), a biotechnology company pioneering the development of targeted genetic medicines, today presented data on its novel approach to the use of BiTEs in solid tumors by utilizing its systemically delivered RedTail platform at the AACR Immuno-Oncology (AACR-IO) conference being held in Los Angeles, California. A link to the poster is available here and on the company\u2019s website. RedTail is Calidi\u2019s systemically delivered virotherapy platform designed to selectively target tumors, remodel the tumor microenvironment (TME), and enable high-level expression of therapeutic genetic payloads directly within the tumor. CLD-401, the lead candidate derived from the RedTail platform, is engineered to express high levels of &hellip; Continue reading &quot;Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-20T13:33:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1ODEyNyM3NDM1Nzg4IzIxOTM4NTQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference\",\"datePublished\":\"2026-02-20T13:33:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference\\\/\"},\"wordCount\":922,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1ODEyNyM3NDM1Nzg4IzIxOTM4NTQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference\\\/\",\"name\":\"Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1ODEyNyM3NDM1Nzg4IzIxOTM4NTQ=\",\"datePublished\":\"2026-02-20T13:33:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1ODEyNyM3NDM1Nzg4IzIxOTM4NTQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1ODEyNyM3NDM1Nzg4IzIxOTM4NTQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference\/","og_locale":"en_US","og_type":"article","og_title":"Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference - Market Newsdesk","og_description":"SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) &#8212; Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (\u201cCalidi\u201d or the \u201cCompany\u201d), a biotechnology company pioneering the development of targeted genetic medicines, today presented data on its novel approach to the use of BiTEs in solid tumors by utilizing its systemically delivered RedTail platform at the AACR Immuno-Oncology (AACR-IO) conference being held in Los Angeles, California. A link to the poster is available here and on the company\u2019s website. RedTail is Calidi\u2019s systemically delivered virotherapy platform designed to selectively target tumors, remodel the tumor microenvironment (TME), and enable high-level expression of therapeutic genetic payloads directly within the tumor. CLD-401, the lead candidate derived from the RedTail platform, is engineered to express high levels of &hellip; Continue reading \"Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-20T13:33:45+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1ODEyNyM3NDM1Nzg4IzIxOTM4NTQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference","datePublished":"2026-02-20T13:33:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference\/"},"wordCount":922,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1ODEyNyM3NDM1Nzg4IzIxOTM4NTQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference\/","name":"Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1ODEyNyM3NDM1Nzg4IzIxOTM4NTQ=","datePublished":"2026-02-20T13:33:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1ODEyNyM3NDM1Nzg4IzIxOTM4NTQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1ODEyNyM3NDM1Nzg4IzIxOTM4NTQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calidi-biotherapeutics-presents-data-on-its-new-approach-to-bispecific-t-cell-engagers-bites-using-its-redtail-platform-at-the-2026-aacr-io-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/938673","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=938673"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/938673\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=938673"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=938673"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=938673"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}